Literature DB >> 24147159

Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer.

Haifa Dbouk1, Hana Ajouz, Ali Shamseddine, Deborah Mukherji, Eileen M O'Reilly, Ali Haydar, David Kelsen, Mohamed Naghy, Mohamed Eloubeidi, Fadi Geara, Leonard Saltz, Ghassan K Abou-Alfa.   

Abstract

Entities:  

Year:  2013        PMID： 24147159      PMCID： PMC3782872     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  18 in total

1.  A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.

Authors:  Peter J Hosein; Gilberto de Lima Lopes; Vitor H Pastorini; Christina Gomez; Jessica Macintyre; Gloria Zayas; Isildinha Reis; Alberto J Montero; Jaime R Merchan; Caio M Rocha Lima
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 4.  Adjuvant therapy for pancreas adenocarcinoma.

Authors:  Eileen M O'Reilly
Journal:  J Surg Oncol       Date:  2012-08-06       Impact factor: 3.454

5.  Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

Authors:  A P Venook; M J Egorin; G L Rosner; D Hollis; S Mani; M Hawkins; J Byrd; R Hohl; D Budman; N J Meropol; M J Ratain
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

6.  Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients.

Authors:  Hyun Jung Kim; Jina Yun; Han Jo Kim; Kyoung Ha Kim; Se Hyung Kim; Tae Hoon Lee; Sang-Cheol Lee; Sang Byung Bae; Chan Kyu Kim; Nam Su Lee; Jong Ho Moon; Sang Heum Park; Kyu Taek Lee; Seong Kyu Park; Jong-Ho Won; Hee Sook Park; Dae Sik Hong
Journal:  Oncol Lett       Date:  2012-03-08       Impact factor: 2.967

7.  Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.

Authors:  Katharina Elisabeth Tschoep-Lechner; Valeria Milani; Frank Berger; Nelli Dieterle; Sultan Abdel-Rahman; Christoph Salat; Rolf-Dieter Issels
Journal:  Int J Hyperthermia       Date:  2012-12-17       Impact factor: 3.914

8.  The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.

Authors:  Robert L Fine; David R Fogelman; Stephen M Schreibman; Manisha Desai; William Sherman; James Strauss; Susan Guba; Riolan Andrade; John Chabot
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-18       Impact factor: 3.333

9.  FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.

Authors:  Alberto Zaniboni; Enrico Aitini; Sandro Barni; Daris Ferrari; Stefano Cascinu; Vincenzo Catalano; Giuseppe Valmadre; Domenica Ferrara; Enzo Veltri; Claudio Codignola; Roberto Labianca
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-11       Impact factor: 3.333

10.  A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.

Authors:  Ana De Jesus-Acosta; George R Oliver; Amanda Blackford; Katharine Kinsman; Edna I Flores; Lalan S Wilfong; Lei Zheng; Ross C Donehower; David Cosgrove; Daniel Laheru; Dung T Le; Ki Chung; Luis A Diaz
Journal:  Cancer Chemother Pharmacol       Date:  2011-07-29       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.